Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-23T11:06:58.488Z Has data issue: false hasContentIssue false
  • English
  • Français

The European Forum for Clinical Management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital cardiac disease

Published online by Cambridge University Press:  03 May 2005

Robert M. R. Tulloh  and
Timothy F. Feltes
Robert M. R. Tulloh
Affiliation:
Department of Paediatric Cardiology, Bristol Royal Hospital for Children, Bristol, United Kingdom
Timothy F. Feltes
Affiliation:
Section of Pediatric Cardiology, Ohio State University and The Heart Center at Children's Hospital, Columbus, Ohio, United States of America
Get access Rights & Permissions [Opens in a new window]

Abstract

A recent, randomised, double-blind, placebo-controlled trial has demonstrated the effectiveness of palivizumab (Synagis®) for prophylaxis against infection by the respiratory syncytial virus in 1,287 young children with congenital cardiac disease. Guidelines for the use of palivizumab in these children considered to be at high risk were published by the American Academy of Pediatrics, followed by similar guidelines from the British Paediatric Cardiac Association, and recommendations from a number of other individual countries, including Canada, Germany, Spain, and France.

In May, 2004, further discussion was held between a group of 15 paediatric cardiologists at a European forum for clinical management held in Munich, Germany. The objective of this forum was to define optimal recommendations on prevention of infection by the respiratory syncytial virus in infants and young children with congenital cardiac disease, appropriate to the clinical needs and style of those practising in paediatrics in individual countries. Participants were invited because of their knowledge of the therapeutic area, and for their experience of using palivizumab for prophylaxis against the respiratory syncytial virus in children with congenitally malformed hearts. Measures to educate the carers of children with such congenital malformations on precautions against infection by the respiratory syncytial virus were discussed, along with the many different aspects of best practice for therapeutic prophylaxis with palivizumab. The most appropriate timing of prophylaxis, recommendations for which children are most likely to benefit from prophylaxis, and suggested protocols were among the issues covered. The recommendations resulting from the discussions are presented in this paper, as a step towards reaching consensus.

Keywords

Bronchiolitispalivizumabrecommendationsguidelines
Type
Original Article
Information
Cardiology in the Young , Volume 15 , Issue 3 , June 2005 , pp. 274 - 278
Copyright
© 2005 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986; 140: 543–546.Google Scholar
Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA 1999; 282: 1440–1446.Google Scholar
Weigl JA, Puppe W, Schmitt HJ. Incidence of respiratory syncytial virus-positive hospitalizations in Germany. Eur J Clin Microbiol Infect Dis 2001; 20: 452–459.Google Scholar
Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J 2002; 21: 629–632.Google Scholar
Greenough A, Cox S, Alexander J, et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 2001; 85: 463–468.Google Scholar
Greenough A, Alexander J, Burgess S, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004; 89: 673–678.Google Scholar
Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000; 137: 865–870.Google Scholar
Gilchrist S, Torok TJ, Gary HE Jr, Alexander JP, Anderson LJ. National surveillance for respiratory syncytial virus, United States, 1985–1990. J Infect Dis 1994; 170: 986–990.Google Scholar
MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982; 307: 397–400.Google Scholar
Simoes EA. Immunoprophylaxis of respiratory syncytial virus: global experience. Respir Res 2002; 3 (Suppl 1): S26–S33.Google Scholar
Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143: 532–540.Google Scholar
American Academy of Pediatrics Committee on Infectious Disease and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus intravenous immune globulin for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112: 1442–1446.
Tulloh RM, Marsh M, Blackburn M, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2003; 13: 420–423.Google Scholar
Joint Committee on Vaccination and Immunisation. Minutes of the meeting held on Friday 1 November 2002 at 10.30. http://www.advisorybodies.doh.gov.uk/jcvi/mins01nov02.htm
Canadian National Advisory Committee on Immunization. Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab). Can Commun Dis Rep 2003; 29: 1–15.
Schmaltz AA. Stellungnahme der Deutschen Gesellschaft für Pädiatrische Kardiologie zur RSV-Prophylaxe mit Palivizumab (Synagis®). Monatsschr Kinderheilkd 2004; 152: 222–223.Google Scholar
Suárez Cabrera P, Malo Concepción P, Maroto E, Santos de Soto J. Recomendaciones de la Sociedad Española de Cardiología Pediátrica y Cardiopatías Congénitas para la prevención de la infección por virus respiratorio sincitial en pacientes con cardiopatía congénita. 2004. http://www.secardioped.org/Google Scholar
Chantepie A, bureau de la Filiale de Cardiologie Pediatrique de la Societe Francaise de Cardiologie. Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society. Arch Pediatr 2004; 11: 1402–1405.
Black CP. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care 2003; 48: 209–231.Google Scholar
Fixler DE. Respiratory syncytial virus infection in children with congenital heart disease: a review. Pediatr Cardiol 1996; 17: 163–168.Google Scholar
Groothuis JR, Nishida H. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab). Pediatr Int 2002; 44: 235–241.Google Scholar
Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, Pfammatter JP, Aebi C. Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. Arch Dis Child 2004; 89: 961–965.Google Scholar
Feltes TF, Simoes EAF. Letter to Editor. Arch Dis Child. http://adc.bmjjournals.com, posted 20/12/04.
Onuzo O. Re: Recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2004; 14: 469.Google Scholar
Keeton B. Re: Recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2004; 14: 469.Google Scholar
Rackham OJ, Thorburn K, Kerr SJ. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus in children with congenital cardiac malformations. Cardiol Young 2005; 15: 251–255.Google Scholar